Market Research Report
Europe Opioids Drug Market Forecast 2019-2027
|Published by||Inkwood Research||Product code||757037|
|Published||Content info||78 Pages
Delivery time: 1-2 business days
|Europe Opioids Drug Market Forecast 2019-2027|
|Published: December 17, 2018||Content info: 78 Pages||
Europe market of opioid drugs is expected to grow at 2.49% CAGR and will reach $XX billion in revenue by 2027. The market trends of Germany, the United Kingdom, France, Italy, Spain & the collective countries from the Rest of Europe are studied for this report.
The growing numbers of opioid crisis are gradually increasing the numbers of lawsuits that are filed against pharmaceutical companies that manufacture and supply opioid drugs and its variants. Overdosage death and widespread addiction caused by opioid use shed a negative impact on its adoption and recommendation by healthcare units. In Europe, the demand for the opioid abuse-deterrent drug is expected to rise mainly because of increasing numbers of cancer patients and the growing aging population demanding for effective pain therapeutics. The Spanish market for opioid drugs is predicted to have rapid growth during the forecast period due to increase prescriptions of a few modified opioid drugs.
The chief companies who profit the most for the European opioid drugs market are Indivior, Inc., Acura Pharmaceuticals, Inc., Johnson & Johnson, Allergan PLC, BioDelivery Sciences International, Inc., Cipher Pharmaceuticals, Inc., Collegium Pharmaceutical, Inc., Daiichi Sankyo, Inc., Hikma Pharmaceuticals PLC, Insys Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Lannett Co. Inc., Lupin Ltd., Mylan NV, Pfizer, Inc., Purdue Pharma LP, Sanofi-Aventis S.A., Sun Pharmaceutical Industries Limited (Sun Pharma), Egalet Corp. and Teva Pharmaceutical Industries Ltd.